Andy Hsieh
Stock Analyst at William Blair
(2.94)
# 1,374
Out of 5,154 analysts
11
Total ratings
66.67%
Success rate
47.52%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Hsieh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AARD Aardvark Therapeutics | Initiates: Outperform | n/a | $5.85 | - | 1 | Dec 12, 2025 | |
| TERN Terns Pharmaceuticals | Upgrades: Outperform | n/a | $42.82 | - | 2 | Nov 3, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Initiates: Outperform | n/a | $8.01 | - | 1 | Feb 28, 2025 | |
| SKYE Skye Bioscience | Initiates: Outperform | n/a | $0.72 | - | 1 | Feb 28, 2025 | |
| ALT Altimmune | Initiates: Market Perform | n/a | $3.54 | - | 1 | Feb 28, 2025 | |
| GPCR Structure Therapeutics | Initiates: Outperform | n/a | $57.73 | - | 1 | Feb 28, 2025 | |
| BIOA BioAge Labs | Initiates: Market Perform | n/a | $20.29 | - | 1 | Feb 28, 2025 | |
| PYXS Pyxis Oncology | Downgrades: Market Perform | n/a | $1.37 | - | 1 | Nov 21, 2024 | |
| LNTH Lantheus Holdings | Initiates: Outperform | n/a | $72.56 | - | 1 | Sep 29, 2023 | |
| ATNM Actinium Pharmaceuticals | Downgrades: Market Perform | n/a | $1.20 | - | 1 | Feb 21, 2023 |
Aardvark Therapeutics
Dec 12, 2025
Initiates: Outperform
Price Target: n/a
Current: $5.85
Upside: -
Terns Pharmaceuticals
Nov 3, 2025
Upgrades: Outperform
Price Target: n/a
Current: $42.82
Upside: -
Corbus Pharmaceuticals Holdings
Feb 28, 2025
Initiates: Outperform
Price Target: n/a
Current: $8.01
Upside: -
Skye Bioscience
Feb 28, 2025
Initiates: Outperform
Price Target: n/a
Current: $0.72
Upside: -
Altimmune
Feb 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $3.54
Upside: -
Structure Therapeutics
Feb 28, 2025
Initiates: Outperform
Price Target: n/a
Current: $57.73
Upside: -
BioAge Labs
Feb 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $20.29
Upside: -
Pyxis Oncology
Nov 21, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.37
Upside: -
Lantheus Holdings
Sep 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $72.56
Upside: -
Actinium Pharmaceuticals
Feb 21, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.20
Upside: -